PURPLE BIOTECH LTD.

Purple Biotech presented its CAPTN-3 tri-specific antibody platform, designed for safer and broader tumor killing by activating both T cells and NK cells with a masking technology. Its lead program, IM1240, is expected to enter clinical trials in 2027, demonstrating strong anti-tumor activity and a 300x improved safety profile in preclinical studies. The company reported $6.1 million in cash as of June 30, 2026, with a runway until mid-2027.

Purple Biotech reported a net income of $0.4 million for the second quarter of 2026, a significant improvement from a net loss of $1.1 million in the prior year, primarily due to a non-cash gain from warrant revaluation. The company's operating loss slightly increased to $1.3 million. Purple Biotech also announced positive preclinical data for its lead candidate, IM1240, at EACR 2026, validating its anti-tumor activity and favorable safety profile, with plans to enter clinical studies in 2027. The company held $6.1 million in cash as of June 30, 2026, providing a cash runway through mid-2027.

Purple Biotech Ltd. reported a net income of $0.4 million for the second quarter of 2026, a significant improvement from a net loss of $1.1 million in the prior year period. The company's cash position stood at $6.1 million as of June 30, 2026, which is expected to fund operations through mid-2027. Additionally, Purple Biotech announced new positive preclinical data for its lead candidate, IM1240, at the EACR 2026 Annual Congress, further supporting its differentiated profile and planned entry into clinical studies in 2027.

Purple Biotech Ltd. announced its Annual General Meeting (AGM) of Shareholders to be held on September 8, 2026. Key proposals include the election of two directors, the approval of compensation terms for CEO Gil Efron as he transitions to Executive Director, Head of Corporate Development, and the adoption of a new compensation policy for executives and directors. Management will also discuss the company's 2025 financial statements.

Purple Biotech presented its corporate overview in June 2026, detailing its CAPTN-3 tri-specific antibody platform for immuno-oncology. The company's lead program, IM1240, a first-in-class tri-specific antibody, is slated to begin clinical trials in 2027, with preclinical data showing significantly improved safety and potent anti-tumor activity. A second program, IM1305, is also in preclinical development. Purple Biotech reported a cash balance of $6.4 million as of March 31, 2026, providing a runway into the first half of 2027, and highlighted the substantial market potential, referencing over $1 billion deals for comparable preclinical masked T-cell engager programs.

Purple Biotech Ltd. presented new preclinical data for its lead CAPTN-3 program, IM1240, at the European Association for Cancer Research (EACR) 2026 Annual Congress. The data highlights IM1240's anti-tumor activity in resistant cancer types and a favorable safety and pharmacokinetic profile validated in non-human primates. These results support the planned advancement of IM1240 towards a first-in-human clinical study in 2027.

Purple Biotech reported its first quarter 2026 financial results, with a net loss of $0.089 million, a decrease from $0.456 million in the prior year, primarily due to non-cash warrant-related income. The company maintained a cash position of $6.4 million as of March 31, 2026, expected to fund operations into 2027. Operationally, Purple Biotech highlighted new positive data for its lead candidate IM1240, established a Scientific Advisory Board for its CAPTN-3 platform, and expanded its AI collaboration with Converge Bio to accelerate antibody development.

Purple Biotech Ltd. announced Q1 2026 financial results and provided an update on its business progress, highlighting new data for its IM1240 tri-specific antibody which demonstrated potent anti-tumor activity across treatment-resistant patient-derived tumor samples. The company also established a CAPTN-3 Scientific Advisory Board and expanded its collaboration with Converge Bio to leverage generative AI for antibody development. Financially, the company reported a net loss of $0.1 million for Q1 2026, a decrease from the prior year, but an increased adjusted operating loss of $2.1 million. Purple Biotech ended the quarter with $6.4 million in cash, providing a runway into 2027.

Purple Biotech Ltd. announced new data from its CAPTN-3 Platform Tri-specific IM1240. This information was disclosed in a press release issued on April 27, 2026, and filed as an exhibit to a Form 6-K report.